Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy

IF 6.1 2区医学 Q1 ONCOLOGY

Cancer Pub Date : 2024-11-26 DOI:10.1002/cncr.35652

Lu Yu MD, Weiming Li MD, Na Xu MD, Xiaoli Liu MD, Bingcheng Liu MD, Yanli Zhang MD, Li Meng MD, Huanling Zhu MD, Xin Du MD, Suning Chen MD, Yu Hu MD, Yongping Song MD, Lichuang Men MSc, Qian Jiang MD

{"title":"Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy","authors":"Lu Yu MD, Weiming Li MD, Na Xu MD, Xiaoli Liu MD, Bingcheng Liu MD, Yanli Zhang MD, Li Meng MD, Huanling Zhu MD, Xin Du MD, Suning Chen MD, Yu Hu MD, Yongping Song MD, Lichuang Men MSc, Qian Jiang MD","doi":"10.1002/cncr.35652","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The objective of this study was to assess patient-reported outcomes (PROs), including health-related quality of life (HRQoL) and anxiety and depression symptoms, and to identify associated variables in patients with tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) in chronic-phase (CP) or accelerated-phase (AP) who were receiving olverembatinib.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Patients in multicenter studies were invited to complete the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 Questionnaire, the Self-Rating Anxiety Scale, and the Self-Rating Depression Scale at baseline and regularly during olverembatinib therapy. The time trends in PROs were estimated with a linear model using a generalized estimating equation based on an independent working correlation matrix. A generalized estimating equation model was used to assess the variables associated with PROs.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In total, 146 patients with CML-CP or CML-AP were included in this study. Scores on seven items from the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 Questionnaire, including global health, physical functioning, emotional functioning, fatigue, dyspnea, diarrhea, and financial difficulties, improved significantly over time during olverembatinib therapy. In multivariate analysis, age younger than 40 years was significantly associated with greater improvement in social functioning (<i>p</i> = .033), and CML-CP (vs. CML-AP) was associated with greater improvements in dyspnea (<i>p</i> = .031) and diarrhea (<i>p</i> = .031) over time. Scores on the Self-Rating Anxiety Scale and the Self-Rating Depression Scale decreased significantly over time during olverembatinib treatment (<i>p</i> < .001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The authors concluded that HRQoL significantly improved over time during olverembatinib therapy in heavily treated patients with TKI-resistant CML, especially among those who were younger and those who had CML-CP. Anxiety symptoms also significantly decreased over time.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694605/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35652","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The objective of this study was to assess patient-reported outcomes (PROs), including health-related quality of life (HRQoL) and anxiety and depression symptoms, and to identify associated variables in patients with tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) in chronic-phase (CP) or accelerated-phase (AP) who were receiving olverembatinib.

Methods

Patients in multicenter studies were invited to complete the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 Questionnaire, the Self-Rating Anxiety Scale, and the Self-Rating Depression Scale at baseline and regularly during olverembatinib therapy. The time trends in PROs were estimated with a linear model using a generalized estimating equation based on an independent working correlation matrix. A generalized estimating equation model was used to assess the variables associated with PROs.

Results

In total, 146 patients with CML-CP or CML-AP were included in this study. Scores on seven items from the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 Questionnaire, including global health, physical functioning, emotional functioning, fatigue, dyspnea, diarrhea, and financial difficulties, improved significantly over time during olverembatinib therapy. In multivariate analysis, age younger than 40 years was significantly associated with greater improvement in social functioning (p = .033), and CML-CP (vs. CML-AP) was associated with greater improvements in dyspnea (p = .031) and diarrhea (p = .031) over time. Scores on the Self-Rating Anxiety Scale and the Self-Rating Depression Scale decreased significantly over time during olverembatinib treatment (p < .001).

Conclusions

The authors concluded that HRQoL significantly improved over time during olverembatinib therapy in heavily treated patients with TKI-resistant CML, especially among those who were younger and those who had CML-CP. Anxiety symptoms also significantly decreased over time.

查看原文本刊更多论文

酪氨酸激酶抑制剂耐药的慢性髓性白血病成人患者接受奥罗瑞巴替尼治疗后的患者报告结果。

研究背景本研究的目的是评估患者报告的结果（PROs），包括健康相关生活质量（HRQoL）、焦虑和抑郁症状，并确定接受奥罗瑞巴替尼治疗的慢性期（CP）或加速期（AP）酪氨酸激酶抑制剂（TKI）耐药慢性髓性白血病（CML）患者的相关变量：多中心研究邀请患者在基线时填写欧洲癌症研究和治疗组织生活质量核心30问卷、焦虑自评量表和抑郁自评量表，并在奥韦拉替尼治疗期间定期填写。使用基于独立工作相关矩阵的广义估计方程线性模型估计了PROs的时间趋势。广义估计方程模型用于评估与PROs相关的变量：本研究共纳入了 146 名 CML-CP 或 CML-AP 患者。在奥罗瑞巴替尼治疗期间，欧洲癌症研究和治疗组织生活质量核心30项问卷中7个项目的得分，包括总体健康、身体机能、情感机能、疲劳、呼吸困难、腹泻和经济困难，随着时间的推移均有显著改善。在多变量分析中，年龄小于40岁与社会功能的改善程度明显相关（p = .033），CML-CP（与CML-AP相比）与呼吸困难（p = .031）和腹泻（p = .031）的改善程度相关。在奥罗瑞巴替尼治疗期间，焦虑自评量表和抑郁自评量表的得分随着时间的推移显著下降（p 结论：奥罗瑞巴替尼治疗期间，焦虑自评量表和抑郁自评量表的得分随着时间的推移显著下降，而抑郁自评量表的得分随着时间的推移显著下降：作者得出结论：随着时间的推移，TKI耐药的CML重症患者在奥维瑞巴替尼治疗期间的HRQoL明显改善，尤其是在年轻患者和CML-CP患者中。随着时间的推移，焦虑症状也明显减轻。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer 医学-肿瘤学

CiteScore

13.10

自引率

3.20%

发文量

480

审稿时长

2-3 weeks

期刊介绍： The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research